You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 8, 2025

Drug Price Trends for emtriva


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for emtriva

Average Pharmacy Cost for emtriva

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
EMTRIVA 200 MG CAPSULE 61958-0601-01 17.40120 EACH 2024-12-18
EMTRIVA 200 MG CAPSULE 61958-0601-01 17.40120 EACH 2024-11-20
EMTRIVA 200 MG CAPSULE 61958-0601-01 17.37973 EACH 2024-10-23
EMTRIVA 200 MG CAPSULE 61958-0601-01 17.37973 EACH 2024-09-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Emtriva Market Analysis and Financial Projection

Market Analysis and Price Projections for Emtriva (Emtricitabine)

Introduction to Emtriva

Emtriva, also known as emtricitabine, is a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV-1 infection. It is often prescribed in combination with other antiretroviral drugs to manage the virus. Here, we will delve into the market analysis and price projections for Emtriva, considering its role within the broader HIV treatment landscape.

Market Size and Growth

The global HIV drugs market, which includes Emtriva, was valued at $30,891.48 million in 2019 and is projected to reach $36,495.47 million by 2027, growing at a compound annual growth rate (CAGR) of around 2.5% during this period[5].

Emtriva in Combination Therapies

Emtriva is frequently used in combination with other drugs such as tenofovir and efavirenz. The market for these combination drugs is significant:

  • The global market for the efavirenz/tenofovir/emtricitabine combination was valued at approximately $3.2 billion in 2022 and is expected to grow at a CAGR of 4.8% from 2023 to 2030[1].
  • The tenofovir/emtricitabine combination drug market was valued at USD 3.4 billion in 2023 and is expected to reach USD 5.6 billion by 2030[4].

Regional Market Analysis

The demand for Emtriva and its combination therapies varies by region:

North America

North America, particularly the United States, is a major market for HIV drugs, including Emtriva. This region is expected to continue its significant contribution to the market growth due to high adoption rates of advanced treatments and the presence of major industry players[1].

Europe

Europe is another key region, with a strong CAGR projected during the forecast period. The market here is driven by advanced healthcare infrastructure and increasing awareness about HIV/AIDS[1].

Asia-Pacific

The Asia-Pacific region is emerging as a high-growth market due to the focus of key players on emerging economies and the rising incidence of HIV infection. This region is expected to offer substantial growth opportunities in the coming years[5].

Price Considerations and Cost-Effectiveness

The cost-effectiveness of Emtriva and its combination therapies is a crucial factor in market dynamics:

  • Generic versions of emtricitabine and other ARV drugs have significantly reduced costs. For instance, the use of generic efavirenz (EFV) was estimated to save nearly $1 billion, making generic regimens very cost-effective[2].
  • The transition to generic versions of tenofovir (TDF) and other components can lead to substantial cost savings. For example, switching from branded to generic TDF-based regimens could save millions of dollars over a few years[2].

Key Players and Market Competition

The market for Emtriva and related combination therapies is highly competitive, with several major players involved:

  • Gilead Sciences, the original developer of Truvada (a combination of emtricitabine and tenofovir), remains a significant player in the market[5].
  • Other key players include Cipla, Mylan Pharmaceuticals, and Sun Pharmaceutical Industries, which offer generic and branded versions of these drugs[1].

Market Trends and Opportunities

Several trends are shaping the market for Emtriva and its combination therapies:

  • Increasing Awareness and Treatment Rates: Growing awareness about HIV/AIDS and improvements in healthcare infrastructure are driving the demand for effective treatments like Emtriva[1].
  • Advancements in Drug Efficacy: Continuous advancements in drug formulations and delivery systems are improving patient adherence and treatment outcomes, contributing to market growth[1].
  • Generic Options: The availability of generic versions of ARV drugs, including emtricitabine, is making treatments more affordable and accessible, which is expected to drive market expansion[2].

Price Projections

Given the trends and market dynamics, here are some price projection insights:

  • Generic Pricing: As more generic versions of emtricitabine and its combination therapies become available, prices are expected to decrease. For example, the wholesale acquisition cost (WAC) and federal supply schedule cost for generic ARV regimens are significantly lower than their branded counterparts[2].
  • Branded vs. Generic: The cost-effectiveness analysis suggests that while branded regimens like those containing tenofovir alafenamide (TAF) may offer slightly improved toxicity profiles, they will remain cost-effective only if their annual cost is not more than $1,000 above that of generically available TDF-based regimens[2].

Key Takeaways

  • Market Growth: The market for Emtriva and its combination therapies is expected to grow significantly, driven by increasing awareness, advancements in drug efficacy, and expanding healthcare infrastructure.
  • Cost-Effectiveness: Generic versions of Emtriva and other ARV drugs are making treatments more affordable and cost-effective.
  • Regional Dynamics: North America, Europe, and the Asia-Pacific region are key markets with varying growth trajectories.
  • Competitive Landscape: The market is highly competitive with major players like Gilead Sciences and several generic drug manufacturers.

FAQs

1. What is Emtriva used for? Emtriva, or emtricitabine, is used in the treatment of HIV-1 infection, often in combination with other antiretroviral drugs.

2. How does the market for Emtriva and its combination therapies look? The market is growing, driven by increasing awareness about HIV/AIDS, advancements in drug efficacy, and expanding healthcare infrastructure. It is valued at billions of dollars and is expected to continue growing over the next few years.

3. What are the key regions for the Emtriva market? North America, Europe, and the Asia-Pacific region are the key markets for Emtriva and its combination therapies.

4. How do generic versions affect the market? Generic versions of Emtriva and other ARV drugs significantly reduce costs, making treatments more affordable and accessible, which drives market expansion.

5. Who are the major players in the Emtriva market? Major players include Gilead Sciences, Cipla, Mylan Pharmaceuticals, and Sun Pharmaceutical Industries.

Sources

  1. Market Report on Efavirenz/Tenofovir/Emtricitabine Combination Drug Market.
  2. Cost Considerations and Antiretroviral Therapy - Clinical Info HIV.gov.
  3. Global Tenofovir Emtricitabine Combination Drug Market Size And Forecast.
  4. Tenofovir/Emtricitabine Combination Drug Market Share, Trends.
  5. Outlook on the HIV Drugs Global Market to 2027 - GlobeNewswire.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.